You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0123 Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry

Alerts

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
THU0123 Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address